Why Is ROIVANT SCIENCES LTD (ROIV) Stock Moving Today?

Roivant Sciences (ROIV) shares rose 5.24% to $36.75 on Tuesday. The primary driver was the announcement of positive Phase 3 trial results for brepocitinib, an FDA-approved therapy known as Lisraya, in the treatment of non-infectious uveitis.

What Happened

Roivant and its subsidiary Priovant Therapeutics reported that the CLARITY-1 and CLARITY-2 trials met their primary endpoints. The company stated that brepocitinib achieved all key secondary endpoints in these late-stage studies for the eye disorder. Roivant filed a Form 8-K with the SEC on October 21, 2026, disclosing the Regulation FD material. The company plans to submit a supplemental New Drug Application in the first half of 2027. Additionally, Roivant announced it will report financial results for the second quarter ended September 30, 2026, on a live call at 8:00 a.m. ET on November 9, 2026. An investor day is also scheduled for December 9, 2026.

What The Data Shows

The stock opened at $35.44, a 1.5% gap from the prior close of $34.92. It reached a session high of $38.56 at 9:25 a.m. ET before settling near $36.58. Volume stood at 2.7 million shares, which is 0.4 times the three-month daily average. The company has a market capitalization of $25.1 billion and remains unprofitable with a trailing twelve-month EPS of $0.49. Revenue declined 67.6% over the same period. The stock has a beta of 1.10 and trades within a 52-week range of $17.28 to $42.50. Over the last 8 sessions, the stock moved 1.4% from $34.44 to $34.92. Recent insider activity includes nine sales totaling $59.8 million over the last 90 days, with no buys recorded. The most recent Form 4 filings involved director Melissa B. Epperly and Eric Venker, President of Immunovant.

What To Watch

Investors will focus on the November 9, 2026, earnings call for the second quarter fiscal 2026 results. The company will also provide a business update on that date, with further details expected at the December 9 investor day.

Why is ROIV stock moving today?

ROIVANT SCIENCES LTD (ROIV) is drawing unusual attention today. Our newswire has captured 1 story on ROIV across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 64/100). The most recent driver: "Roivant Sciences price target raised to $56 from $46 at Citi" (The Fly).

Is ROIV a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ROIV coverage reads 64/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.